Dendritic Cell Maturation Composition for Antigen-Specific Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for maturing dendritic cells for immunotherapy, such as using monocyte conditioned medium or cytokine cocktails, are not standardized and do not consistently produce fully mature dendritic cells, limiting their effectiveness in inducing potent antigen-specific immunity against cancer.
Innovation Solution
A composition comprising Interleukin-1β, Interleukin-6, Tumor necrosis factor-α, Interferon gamma, Prostaglandin E2, and Picibanil (OK432) is used to mature dendritic cells, enhancing their immune response-inducing potential and increasing antigen-specific immune responses while reducing non-specific responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MCM (monocyte conditioned medium) is used for maturing dendritic cells, then dendritic cell maturation is achieved, but the process lacks uniformity and consistency across different preparations
Solution Approach 1:
The patent applies parameter changes by defining specific concentrations and combinations of cytokines (IL-1β, IL-6, TNF-α, PGE2) to standardize the maturation process. This transforms the variable MCM approach into a controlled protocol with fixed parameters, ensuring uniform dendritic cell maturation across different preparations while maintaining process simplicity.
2Reliability
If a cytokine cocktail (IL-1β, IL-6, TNF-α, PGE2) is used for maturing dendritic cells, then stable production with high function is achieved, but the dendritic cells are not sufficiently mature
Solution Approach 1:
The patent applies composite materials by combining the cytokine cocktail (IL-1β, IL-6, TNF-α, PGE2) with Picibanil (OK432) to create a composite maturation formulation. This composite approach leverages the stability-inducing properties of the cytokines while adding Picibanil to achieve sufficient dendritic cell maturity, thereby resolving the contradiction between production stability and cell maturity.
3Ease of manufacture
If dendritic cells are not fully matured, then the preparation process is simpler, but the immunotherapeutic effect is insufficient
Solution Approach 1:
The patent applies preliminary action by incorporating Picibanil (OK432) into the maturation protocol from the outset, rather than attempting to mature dendritic cells in multiple sequential steps. This preliminary inclusion of the maturation-enhancing agent ensures that dendritic cells reach full maturity during the standard preparation timeframe, achieving both manufacturing simplicity and immunotherapeutic effectiveness simultaneously.
Data Source
Figure 1A~1B
Figure 2
Figure 3
AI summary
The present invention relates to a composition for maturing dendritic cells, comprising, as a maturation-promoting factor, Interleukin-1β (IL-1β), Interleukin-6 (IL-6), Tumor necrosis factor-α (TNF-α), Interferon-γ (IFN-γ), Prostaglandin E2 (PGE2), Picibanil (OK432) and/or Poly IC. The composition for maturing dendritic cells of the present invention may have the effects of not only improving the ability of dendritic cells to induce an immune response, but also of decreasing the antigen non-specific immune response of dendritic cells and increasing antigen-specific immune response of dendritic cells, thus maximizing the effects of immunotherapy.